Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVIG-SN 10% + Aspirin in Pediatric Kawasaki Disease
NCT04003844Phase 4Completed
- Sponsor
- GC Biopharma
- Start
- Feb 2019
- Primary completion
- Nov 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of IVIg-SN 10% in Kawasaki disease (KD), sponsored by GC Biopharma. Primary endpoint: Incidence of coronary artery lesions at 7 weeks. Started Feb 2019; status: completed.
02
Drugs
IVIg-SN 10%
03
Conditions
Kawasaki disease (KD)
Beyond the preview
Go deeper on NCT04003844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04003844.